Exploring the role of oncolytic viruses in hepatobiliary cancers.
Immunotherapy
; 10(11): 971-986, 2018 08.
Article
en En
| MEDLINE
| ID: mdl-29900755
ABSTRACT
The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14.1 vs 6.7 months; p = 0.08) in a Phase II study. A Phase III study with JX-594 and sorafenib in advanced HCC is ongoing. No survival benefit in HCC was seen with two other recombinant adenoviruses (Ad-TK and DL1520). Several preclinical trials using oncolytic viruses in HBC showed promising results, warranting clinical studies.
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Asunto principal:
Virus Vaccinia
/
Carcinoma Hepatocelular
/
Virus Oncolíticos
/
Viroterapia Oncolítica
/
Sorafenib
/
Neoplasias Hepáticas
Tipo de estudio:
Systematic_reviews
Idioma:
En
Revista:
Immunotherapy
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos